The cellular signals controlling the formation of cardiomyocytes, vascular smooth muscle, and endothelial cells from stem cell-derived mesoderm are poorly understood. To identify these signals, a mouse embryonic stem cell (ESC)-based differentiation assay was screened against a small molecule library resulting in a 1,4-dihydropyridine inducer of type II TGF-b receptor (TGFBR2) degradation-1 (ITD-1). ITD analogs enhanced proteasomal degradation of TGFBR2, effectively clearing the receptor from the cell surface and selectively inhibiting intracellular signaling (IC 50 $0.4-0.8 mM). ITD-1 was used to evaluate TGF-b involvement in mesoderm formation and cardiopoietic differentiation, which occur sequentially during early development, revealing an essential role in both processes in ESC cultures. ITD-1 selectively enhanced the differentiation of uncommitted mesoderm to cardiomyocytes, but not to vascular smooth muscle and endothelial cells. ITD-1 is a highly selective TGF-b inhibitor and reveals an unexpected role for TGF-b signaling in controlling cardiomyocyte differentiation from multipotent cardiovascular precursors.
SUMMARY
The cellular signals controlling the formation of cardiomyocytes, vascular smooth muscle, and endothelial cells from stem cell-derived mesoderm are poorly understood. To identify these signals, a mouse embryonic stem cell (ESC)-based differentiation assay was screened against a small molecule library resulting in a 1,4-dihydropyridine inducer of type II TGF-b receptor (TGFBR2) degradation-1 (ITD-1). ITD analogs enhanced proteasomal degradation of TGFBR2, effectively clearing the receptor from the cell surface and selectively inhibiting intracellular signaling (IC 50 $0.4-0.8 mM). ITD-1 was used to evaluate TGF-b involvement in mesoderm formation and cardiopoietic differentiation, which occur sequentially during early development, revealing an essential role in both processes in ESC cultures. ITD-1 selectively enhanced the differentiation of uncommitted mesoderm to cardiomyocytes, but not to vascular smooth muscle and endothelial cells. ITD-1 is a highly selective TGF-b inhibitor and reveals an unexpected role for TGF-b signaling in controlling cardiomyocyte differentiation from multipotent cardiovascular precursors.
INTRODUCTION
The ability to control stem cell cardiogenesis is critical to realize the promise of pluripotent stem cells as a source of cells for replacement therapies. Moreover, an improved understanding of the signals that regulate replication and differentiation of cardiac progenitors might reveal mechanisms that underlie the limited potential of the adult heart to replace muscle cells after injury and ultimately could lead to strategies for in vivo regeneration therapies (Sturzu and Wu, 2011 ). An important approach to defining the signals that drive stem cell cardiogenesis has been to mimic embryological mechanisms for mesoderm induction and cardiogenic patterning (Burridge et al., 2012) . Although successful in revealing the underlying mechanisms of early differentiation events, little is known about the signals that drive later steps of cardiogenesis that may be key to achieving therapeutic regeneration.
Unbiased screening of small molecules in phenotypic assays can overcome some of the limitations of embryology studies and is thus an alternate approach to study gene, protein, or pathway function in complex biological systems (Willems et al., 2011) . Here, we describe a large-scale, image-based screen to identify novel small molecule probes that would stimulate the specification of cardiac cells from uncommitted mesoderm in embryonic stem cells (ESCs) . One of the most active compounds was a 1,4-dihydropyridine, which we named inducer of TGF-b type II receptor degradation (ITD). ITD and its analogs promote cardiomyocyte differentiation specifically via degradation of the TGF-b type II receptor (TGFBR2), revealing a role for TGF-b itself as a repressor of cardiomyocyte fate. Moreover, ITDs comprise selective TGF-b inhibitors that do not block the closely related Activin A signaling pathway and represent reagents for exploring TGF-b function in various biological contexts such as embryonic development and models of disease.
RESULTS

A Cardiogenesis Screen Identifies a Novel TGF-b-Selective Inhibitor
A mouse ESC (mESC) assay using an image-based Myh6-GFP reporter readout was screened between days 2 and 6 of differentiation, as uncommitted mesoderm (T/Bra + ) cells become specified as cardiac. The assay identified a 1,4-dihydropyridine, which we named ITD-1 (inducer of TGF-b type II receptor degradation-1). ITD-1 optimally promoted cardiogenesis and beating cell clusters when added from day 3 to day 5 of differentiation ( Figures 1A-1C and Movie S1 available online). In contrast, ITD-1 completely abolished cardiogenesis when added before mesoderm induction, i.e., days 1-3 of differentiation (Figures 1B and 1C) , suggesting a biphasic effect of ITD-1 during differentiation of mESCs, inhibiting mesoderm early and inducing cardiac fate later. Dihydropyridines are well-known calcium channel blockers, so we asked whether this mechanism was responsible for any of the ITD-1 activities, but no evidence was found for a role through calcium inhibition ( Figure S1 ). To facilitate target identification of ITD-1, a panel of tyrosine kinase inhibitors was screened in the day 3-5 cardiogenic window, revealing that blocking Activin A and/or TGF-b signaling upregulated cardiogenesis significantly (Table S1 ). HEK293T cells were transfected with a Smad4 response element driving luciferase (SBE4-Luc) to test whether ITD-1 blocked Activin A/ Nodal and/or TGF-b signaling, which utilize the same intracellular signaling cascade through Smad4. ITD-1 strongly inhibited TGF-b2 signaling with similar efficacy (92% versus 99%, respectively) but with lower potency compared to SB-431542, a ACVR1B/TGFBR1 kinase inhibitor (IC 50 = 850 nM versus 70 nM, respectively) and was a weak and partial inhibitor of Activin A signals ( Figures 1D, 1E , and 1M). Toxicity was not responsible for the observed inhibitory activity of ITD-1, and other developmentally important pathways such as Wnt or BMP signaling were not inhibited by ITD-1 ( Figure S2 ). To understand whether TGF-b2 and Activin A inhibition was through a shared target, we pursued a chemical biology approach asking whether or not we could generate ITD-1 analogs that would selectively target the TGF-b pathway and not the Activin A pathway. Optically pure (+)-and (À)-enantiomers of ITD-1 (chiral center at the 4-position) showed that the inhibitory effect was well separated stereochemically for TGF-b2, but not for Activin A, suggesting a highly selective mechanism for TGF-b2 inhibition, distinct from that of the weak Activin A inhibition (Figures 1F, 1G, and 1M) . This finding prompted a screen of ITD-1 analogs to increase the selectivity for TGF-b2 relative to Activin A. From more than 200 analogs, one highly selective candidate, named ITDts (ITD TGF-b selective), retained TGF-b2 inhibition activity but lost Activin A inhibition activity even at 5 mM ( Figures 1H-1K and 1M ). Interestingly, a structural homolog of ITDts, ITD-2, where only the 4-CF 3 group was replaced by a 4-CH 3 group, retained the weak activity against Activin A ( Figures 1H-1K and 1M) .
We next evaluated whether ITD-1 is functionally selective in a defined stem cell system. We used Cripto À/À mESCs, which lack the essential coreceptor needed to respond to Nodal, to remove any confounding effects that endogenous Nodal might have if stimulated in response to exogenous Activin A or TGF-b. ITD-1 (5 mM) effectively blocked induction of the Activin A/Nodal/TGF-b target gene Lefty1 in response to TGF-b2 but not to Activin A ( Figure 1L ). Because ITD-1 is functionally selective, we therefore used it in subsequent biological studies but confirmed key results with ITDts, which has poorer chemical stability in cell culture media.
ITD-1 Blocks TGF-b Signaling at the Receptor Level
The TGF-b signaling pathway was then probed at multiple levels to determine the point of inhibition. ITD-1 did not block the kinase activity of either type I (TGFBR1) or type II (TGFBR2) TGF-b receptors ( Figures S3A and S3B ), but ITD-1 potently blocked phosphorylation of the effector SMAD2/3 proteins induced by TGF-b2 and only minimally in response to Activin A ( Figures 1N  and 1O ), corroborating the findings that ITD-1 is selective for TGF-b. Consequently, ITD-1 reduced transcriptional levels of Lefty1 in Cripto À/À mESCs and needed $3 hr more to inhibit
Lefty1 expression compared to SB-431542 ( Figure 1P ). These results demonstrate that ITD-1 targets the TGF-b pathway at the receptor level but uses a different and more selective mechanism compared to kinase inhibitors such as SB-431542 ( Figure 1Q , Table S2 ).
ITD-1 Specifically Targets TGFBR2 to the Proteasome
The above findings prompted us to investigate some of the dynamic processes of receptor internalization, degradation, and recycling that regulate the ability of the receptor to signal (Chen, 2009) . After binding the TGF-b ligand, TGFBR2 associates with TGFBR1, and the resulting ligand-receptor complex is internalized, as a requisite for signaling. By using an overexpressed extracellularly HA-tagged TGFBR2-mCherry fusion protein (HA-TGFBR2-mCherry), which is internalized in the presence of TGF-b2 ligand, we found that ITD-1 did not block immediate internalization of TGFBR2, in contrast to SB-431542, which abolished internalization ( Figure S3C ). We then asked whether ITD-1 interfered with receptor recycling and/or degradation through the lysosome or proteasome (Di Guglielmo et al., 2003) . ITD-1 did not affect TGFBR1 when overexpressed in HEK293T (Figures 2A and 2B ), but strongly downregulated TGFBR2 protein levels ( Figures 2C and 2D ). ITD-1 similarly decreased endogenous TGFBR2 levels in several human cell lines, demonstrating that the ITD-1 effect was not an artifact of overexpression ( Figures 2E, 2F , S4A, and S4B).
To distinguish whether ITD-1 decreased cell surface or total TGFBR2 levels, we developed a flow cytometry assay with the HA-TGFBR2-mCherry vector that allowed the cell surface (extracellular HA-tag immunostaining) and total (mCherry fluorescence) TGFBR2 levels to be measured independently in the same experiment. Both HA-tag and mCherry levels declined in response to ITD-1, indicating that ITD-1 cleared TGFBR2 from the cell surface and targeted it for degradation ( Figure 2G ). The effect of ITD-1 was also observed on endogenous cell surface TGFBR2 and was selective, as shown by the fact that ITD-1 did not affect other tyrosine kinase receptors ( Figures S4C-S4F ). ITD-1 diminished both the number of cells with TGFBR2 receptor, and the number of receptors per cell in a dose-dependent manner ( Figures 2H and 2I ). ITD-1 downregulated HA-TGFBR2 and TGFBR2-mCherry with nearly the same potency (IC 50 = 1.05 and 1.31 mM, respectively), suggesting a common mechanism, although the maximal depletion of HA-TGFBR2 was greater (E max = $80% versus $50%), consistent with the fact that ITD-1 acts by enhancing degradation rather than by blocking synthesis, which would affect cell surface and intracellular receptor pools equally ( Figure 2I ). At least 6 hr were needed for ITD-1 to reduce TGFBR2 levels, with a maximum reduction by 24 hr of treatment ( Figure 2J ).
To gain insight in the degradation mechanism of ITD-1, cells were treated with lysosome or proteasome inhibitors. ITD-1 reduced the levels of TGFBR2-mCherry fluorescence per cell, resulting in an increased number of TGFBR2-mCherry lo cells at ( Figure 2L ). Additional support for induced degradation as the mechanism of ITD-1 action was the robust structure activity relationship (SAR) between TGFBR2 degradation and inhibition of TGF-b2 SBE4-Luc activity (R 2 > 0.8) ( Figure 2M ). Because TGFBR2 was targeted to the proteasome, we examined ubiquitination of TGFBR2 but found no evidence of mono-or polyubiquitination ( Figure S5 ). Taken together, the ITD class of molecules comprises selective TGF-b inhibitors that function by diverting TGFBR2 to the proteasome through an ubiquitin-independent mechanism.
Mesoderm Induction in ESCs Requires TGF-b
Inhibition of mesoderm formation by ITD-1 (Figures 1B and 1C) indicated that TGF-b was essential for this process, which was unexpected because prior studies had implicated only the TGF-b family member Nodal, Wnt, and BMP (Burridge et al., 2012) . Although TGF-b addition can mimic the native role of Nodal in generating mesoderm and heart cells in ESCs, it is not known to normally do so in either embryos or ESC cultures (Behfar et al., 2002) . ITD-1 was therefore used to study the role of TGF-b in mesoderm induction. ESC cultures were exposed to ITD-1 from day 1 of differentiation and analyzed for germ layer segregation ( Figures 3A-3C ). qRT-PCR analysis of mesoderm, endoderm, and ectoderm markers at day 5 of differentiation indicated that ITD-1 given at day 1 of differentiation induced ectoderm at the expense of mesoderm ( Figure 3B ). Consequently, on day 10 of differentiation, markers for mesoderm tissues such as heart, endothelium, smooth muscle, and blood were all downregulated, whereas neural markers were upregulated ( Figure 3C ). A T-GFP mESC reporter line was then used to quantify mesoderm inhibition by ITD-1 compared to small molecule inhibitors of TGF-b and Activin A/Nodal (SB-431542 and LY-364947), Wnt (IWP), and BMP signaling (Dorsomorphin, DM), which are known to drive mesoderm ( Figures 3D and 3E ). Inhibition of Wnt and Activin A/TGF-b pathways diminished the number of mesoderm cells, similarly to ITD-1 ( Figures 3D and 3E ), suggesting that all three factors are involved. However, BMP inhibition did not affect mesoderm as documented previously (Yuasa et al., 2005) . ITD-1 did not inhibit Wnt signaling ( Figures S2B-S2E) , and because ITD-1 retained weak activity against Activin A/Nodal signaling, it was evaluated in the Cripto À/À mESC assay, revealing that ITD-1 selectively blocked mesoderm induced by TGF-b but not by Activin A (Figures 3F and 3G ). To confirm the specific involvement of TGF-b, the chemical tools described above were applied to correlate mesoderm inhibition with TGF-b signaling inhibition. Enantiomeric separation in the T-GFP assay was similar to TGF-b2 signaling inhibition ( Figure 3H ) and ITDts also reduced the number of T-GFP-positive cells ( Figure 3I ). Moreover, the correlation between both activities was very strong as shown through SAR analysis ( Figure 3J ). The ITD class of molecules thus exposed an essential and specific role for TGF-b during mesoderm formation in ESCs.
TGFBR2 Degradation Specifically Promotes Cardiac Lineages in ESC
The procardiac effect of ITD-1 between days 3 and 5 of mESC differentiation suggested a specific and unappreciated role for TGF-b in regulating cardiac cell fate ( Figures 1B, 1C , 4A, and 4B). SAR analyses showed a strong correlation between TGF-b inhibition and cardiomyocyte differentiation (R 2 = 0.78), comparable to that between cardiogenesis and mesoderm inhibition ( Figures 4C and 4D ). Moreover, analysis of Myh6-GFP 
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TGFBR2 Degradation Drives ESC Cardiogenesis expression in mESCs demonstrated that ITD-1, ITD-1(+), ITDts, and ITD-2 all drove cardiomyogenesis as well as SB-431542 and LY-364947, whereas ITD-1(À) did not ( Figures 4E-4G ), all consistent with an inhibitory effect of TGF-b on cardiomyocyte differentiation. Similarly, siRNA knockdown of Tgfbr1 or Tgfbr2 alone was sufficient to promote cardiac fate, whereas knockdown of Acvr1b and thus Activin signaling had no effect (Figure 4H) , confirming a repressive role of TGF-b on cardiomyocyte development at this time. Conversely, addition of TGF-b2 and not Activin A inhibited cardiogenesis in the day 3-5 window of differentiation, bolstering the findings obtained with chemical-and siRNA-mediated knockdowns of TGFBR2 ( Figure 4I ). To determine the developmental stages when TGF-b affected cardiac differentiation and whether other cardiovascular lineages were also affected, markers of the different germ layers, progenitors, and lineages were examined at different time points by qRT-PCR. At day 5 of differentiation, mesoderm, endoderm, and ectoderm markers were unaltered, and only the cardiac progenitor-specific markers Kdr and Mesp1 were increased by ITD-1 ( Figure 4J ). Furthermore, only cardiac-specific markers were increased at day 10, whereas none of the vascular or hematopoietic markers were affected. TGF-b thus specifically repressed the formation of cardiomyocytes at this stage of differentiation ( Figure 4K ).
To understand the true magnitude of ITD-1 treatment toward cardiac induction from ESCs, we asked whether TGF-b inhibition played a similarly specific role in promoting cardiomyocyte specification in a completely optimized cardiac differentiation protocol in human ESCs (hESCs). H9 cells were optimally differentiated to cardiomyocytes, with ITD-1 added during mesoderm patterning (day 1-5) and cultures were surveyed for cardiovascular markers by flow cytometry and qRT-PCR at day 6 of differentiation ( Figures 4L and 4M ). Whereas SB completely blocked cardiogenesis at this stage because of Activin A dependence (data not shown), ITD-1 potently enhanced TNNT2 + cardiomyocyte yield by $30% resulting in $60% cardiomyocytes and was also visible on the mRNA level (Figures 4L and 4M) . A slight repression of vascular and hematopoietic markers was also observed ( Figure 4M ). These findings demonstrate that endogenous TGF-b regulates the yield of cardiomyocytes in hESCs, even under fully optimized and defined media conditions. In summary, ITD-1 and its analogs unraveled a conserved mechanism that exclusively directs cardiac fate in ESCs through temporal inhibition of TGF-b signaling.
DISCUSSION
Screening of small molecules in a complex biological system through a phenotypic read-out can lead to the identification of novel probes of the biology of a cellular system. Such probes can then be linked to specific pathways or mechanisms and may lead to the identification of novel drug targets (Ao et al., 2011; Willems et al., 2011) . Therefore, we developed imagebased screens in ESCs to discover new pathways and/or mechanisms in cardiogenesis, in particular as a means to gain insight into endogenous regeneration. The molecule described here acts when uncommitted mesoderm cells become specified to a cardiac fate. ITD-1 treatment at this stage in an optimal hESC assay indicates that manipulation of endogenous TGFb signaling is an important step to refine protocols that enhance cardiomyocyte differentiation, which can be highly variable in different human embryonic and induced pluripotent stem cell lines (Kattman et al., 2011) .
1,4-dihydropyridines are well-known inhibitors of calcium channels (Edraki et al., 2009 ), but that mechanism was ruled out. By screening a panel of tyrosine kinase inhibitors that span a wide range of pathways, ITD-1 was found to inhibit the Activin A/TGF-b pathway specifically. Activin A and TGF-b act similarly in that they bind homologous receptors to form ligand-receptor complexes that activate an identical intracellular network of Smad2/3/4 proteins (Wharton and Derynck, 2009 ). Clear stereochemical separation for the strong TGF-b and no separation for the weak Activin A inhibitory activities suggested that the molecular target responsible for effective TGF-b inhibition differs from that which accounts for the lower level of activity against Activin A. The identification of ITDts, which is highly selective for TGF-b, substantiates that idea. Pharmacological separation of the inhibitory effect on the two signaling pathways thus indicates that ITD-1 and analogs bind a molecular target that uniquely affects TGF-b signaling. Therefore, ITD-1 and ITDts are small molecule inhibitors that are highly selective for TGFb relative to the Activin/Nodal signaling pathways.
A key observation of this study is that ITD-1 blocks TGF-b signaling by promoting degradation of TGFBR2. TGF-b receptor levels on the cell surface are dynamically regulated by vesiclemediated ligand-triggered trafficking, recycling, and lysosome degradation ( Figure S6A , branch 1), as well as by direct proteasomal degradation ( Figure S6A , branch 2; Chen, 2009; Di Guglielmo et al., 2003) . ITD-1 does not target the signaling/ recycling/lysosome degradation loop. Instead, ITD-1 drives proteasomal degradation of TGF-b receptors as MG132 and Bortezomib rescued receptor degradation ( Figure S6A, branch 2) . However, previous studies described equal proteasomal degradation of both TGFBR1 and TGFBR2 through the ubiquitin ligase Smurf2 (Di Guglielmo et al., 2003) . Our data on ITD-1 differ from this mechanism since TGFBR2 but not TGFBR1 levels are affected, and the process is ubiquitin independent. Therefore, we suggest that there may be a third mechanism for the specific degradation of TGFBR2 that is enhanced by ITD-1 (K) Representative flow cytometry analysis for total TGFBR2 (TGFBR2-mCherry). ITD-1 reduced the TGFBR2-mCherry level per cell (high to low) compared to DMSO vehicle (blue versus red, left). Chloroquine (CQ) did not affect TGFBR2-mCherry levels on ITD-1-treated cultures (orange versus blue, middle), while MG132 (MG) or Bortezomib (BZ) treatment rescued the ITD-1 effect (green versus blue, right). ( Figure S6A, branch 3) . Although the direct target of ITD-1 remains to be elucidated, several groups have reported different half lives for TGFBR1 and TGFBR2, consistent with the idea that distinct degradation processes may exist to clear these receptors from the cell surface (Wells et al., 1997) . It remains possible that ITD-1 directly binds TGFBR2 to drive its internalization and degradation. Interestingly, TGFBR2 appears to be exclusively downregulated in several human cancers, and in renal carcinomas this reduction has been attributed to increased proteasomal degradation (Fukasawa et al., 2010; Meng et al., 2011) . ITD-1 might therefore be useful as a probe to understand how the altered dynamics of TGFBR2 trafficking contributes to cancer. Through its high selectivity for TGF-b, ITD-1 revealed a biphasic role of TGF-b signaling in ESC cardiogenesis ( Figure S6B ). When applied early in the differentiation process, ITD-1 prevented mesoderm formation and enhanced neuroectodermal fates. A direct role for TGF-b in mesoderm induction was unanticipated because Nodal (and Activin A) and Wnt are thought to be the principal effectors of the mesoderm and neuroectoderm fate choice in ESCs and mouse embryos (Naito et al., 2006; Perea-Gomez et al., 2002) . TGF-b is expressed in differentiating ESCs and embryos and can induce mesoderm if provided exogenously, but Tgfbr1-and Tgfbr2-null embryos do form mesoderm (Larsson et al., 2001; Oshima et al., 1996) . Thus, our data provide evidence for the requirement of TGF-b in mesoderm/neuroectoderm induction in mESCs and potentially in embryos, although compensatory and/or other mechanisms may allow mesoderm formation in Tgfbr1 and Tgfbr2 mutant embryos.
Additionally, ITD-1 stimulated cardiomyocyte differentiation from uncommitted mesodermal progenitors in mouse and human ESCs, indicating that TGF-b represses cardiac fate at this developmental stage. Interestingly, inhibition of the TGFb signaling pathway at this time did not increase vascular smooth muscle or endothelial markers or cell number, further substantiating the idea that ITD-1 specifically stimulated cardiac differentiation from a cardiovascular progenitor ( Figure S6B , light blue cell). In addition, TGF-b inhibition continues to enhance cardiogenesis at considerably later stages (>day 8) by enhancing proliferation of immature cardiomyocytes (Kitamura et al., 2007) . In embryos, TGF-b ligands are expressed in the newly forming cardiac crescent where cardiomyocyte-committed cells arise and may thus naturally contribute to the proper apportioning of cardiomyocyte versus other cardiovascular lineages (Dickson et al., 1993; Kitamura et al., 2007) .
In summary, a phenotypic screen of ESC cardiogenesis yielded ITD-1, which is a selective TGF-b inhibitor. ITD-1 acts by stimulating clearance of TGFBR2 from the cell surface and subsequent proteasomal degradation. The chemical biology approach revealed that TGF-b plays a critical, biphasic role in the formation of cardiovascular derivatives from ESCs, first by promoting mesoderm induction and subsequently by inhibiting cardiomyocyte differentiation specifically. Moreover, ITD-1 is a potentially valuable reagent, not only to study ESC differentiation, but also to probe the role of TGF-b signaling in pathological processes such as cancer, fibrosis, and adult cardiovascular disease.
EXPERIMENTAL PROCEDURES
Embryonic Stem Cell Culture and Differentiation Assays mESC lines CGR8 carrying a Myh6-GFP, J1 carrying a T-GFP reporter, and Cripto À/À ESCs were maintained as described in Supplemental Experimental
Procedures. For screening, Myh6-GFP ESCs were seeded and differentiated in 384-well plates. About 17,000 compounds from the DIVERSet library (Chembridge) were added from day 2 to day 6 of differentiation. ITD-1, SB-431542 (Sigma), LY-364947 (Cayman Chemical), and tyrosine kinase inhibitor panel (EMD/Millipore) treatments were performed as indicated. Myh6-GFP-positive cells were imaged on an InCell 1000 System (GE Healthcare) and GFP levels from images were quantified with Cyteseer (Vala Sciences).
Mesoderm inhibition assays with T-GFP and Myh6-GFP cells were performed as suspension cultures in serum-containing media. Embryoid bodies (EBs) formed in differentiation media were exposed to ITDs, SB-431542, LY-364947, Dorsomorphin (Tocris), or IWP (EMD/Millipore) at day 1 of differentiation.
For the Cripto À/À mESC assay, cells were transferred to serum-free conditions and were treated at day 2 of EB formation with Wnt3a, 15 ng/ml TGF-b2 (EMD/Millipore), 10 ng/ml BMP4 (R&D Systems), or 15 ng/ml Activin A (R&D Systems) in the presence of indicated compounds. H9 hESC were differentiated as EBs in StemPro34 (GIBCO) in ultra-low attachment plates. EBs were optimally differentiated with BMP4, Activin A, bFGF (Sigma), VEGF (R&D Systems), and DKK1 (R&D Systems) as described (Kattman et al., 2011) , with addition of ITD-1 from day 1 to day 5.
Quantitative Reverse-Transcription PCR cDNA samples, synthetized from total RNA with the Quantitect RT kit (QIAGEN), were run on a LightCycler 480 (Roche) with LC480 Sybr Green master mix (Roche). Primers are available at http://www.rtprimerdb.org/ and primer ID numbers are listed in Supplemental Experimental Procedures.
SBE4-Luciferase Assays
HEK293T cells, grown in DMEM-high glucose with 1% FBS, were transfected with SBE4-Luciferase plasmid and CMV-Renilla-Luciferase with Lipofectamine 2000 (Invitrogen). After 12 hr of adhesion, cells were induced with either TGF-b2 (15 ng/ml) or Activin A (15 ng/ml) and inhibitors were added simultaneously. Luminescence was measured through the Dual-Glo kit (Promega).
Receptor Degradation Assays TGFBR1, extracellularly HA-tagged TGFBR2, HA-TGFBR2-mCherry fusions, pcDNA3.1, or PGK-GFP plasmids were transfected in HEK293T as above and treated >6 hr later with ITD-1 for the indicated time points. Chloroquine (Sigma), Bortezomib (Selleck Chemicals), or MG132 (Sigma) were added 3 hr after ITD-1 treatment.
Flow Cytometry
Cultures were dissociated with enzyme-free cell dissociation buffer (GIBCO) (or trypsin for cardiomyocytes) and analyzed on a FACSCanto or LSRFortessa (BD Biosciences). For intracellular stains, cells were permeabilized with saponin (Sigma) before staining. Single cells were stained for 30 min with (F and G) T gene expression in Cripto À/À mESCs to assess whether ITD-1 can block the ability of Activin A (F) or TGF-b2 (G) to induce mesoderm. *p < 0.05 compared to no Activin A/TGF-b2 control; # p < 0.05 compared to Activin A/TGF-b2 alone; NS, not significant. 
Image-based
Myh6-GFP
Pecam1
Gating Western Blotting Cells were washed in cold PBS, collected with enzyme-free dissociation buffer, and lysed with ice-cold RIPA buffer supplemented with protease and phosphatase inhibitors (Sigma). Lysates were run on 10% SDS-tris glycine gels (Invitrogen) and transferred to 45 mm PVDF membranes, which were blocked and stained in 5% w/v skim milk in TBST. Detection was performed with the ECL Plus detection kit (Abcam) or with an Odyssey system (LICOR). Antibodies are listed in the Supplemental Experimental Procedures.
Statistic Analysis of Samples
All data are represented as the mean with error bars indicating SEM for at least three biological replicates; p values were obtained by a Student's t test. Dose response curve fitting and EC 50 /IC 50 calculation using the (log)agonist versus normalized response equation for induction and the (log)inhibitor versus normalized response equation for inhibition were done in Prism 5 (GraphPad Software). Toxic doses were removed from EC 50 or IC 50 analysis, as judged by Renilla luciferase levels, Alamar Blue cell viability assays, or microscopy.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, six figures, two tables, and one movie and can be found with this article online at http://dx.doi.org/10.1016/j.stem.2012.04.025.
